Overview
PhoreMost is a UK-based biopharmaceutical company specializing in targeted protein degradation (TPD) through its proprietary SITESEEKER and GlueSEEKER platforms. These technologies enable phenotypic screening to identify novel druggable targets across the proteome and develop molecular glue degraders for oncology and inflammation. The company collaborates with partners like Arvinas to advance degrader therapeutics.
Frequently asked questions
- What are PhoreMost's key platforms for targeted protein degradation?
- PhoreMost's SITESEEKER platform performs phenotypic screening to identify novel druggable targets in live cells, while GlueSEEKER enables high-throughput discovery of molecular glue degraders by engineering E3 ligases.
- What therapeutic areas does PhoreMost target?
- PhoreMost focuses on oncology and inflammation, progressing a pipeline of degrader therapeutics for undruggable targets.
- Does PhoreMost offer partnerships or collaborations?
- Yes, PhoreMost collaborates with companies like Arvinas on multiple therapeutic targets, providing research funding, milestones, and access to its screening platforms.